🇺🇸 antibiotic prophylaxis in United States

24 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 24

Most-reported reactions

1. Neutropenia — 4 reports (16.67%)
2. Hepatotoxicity — 3 reports (12.5%)
3. Herpes Zoster — 3 reports (12.5%)
4. Cardiac Failure Congestive — 2 reports (8.33%)
5. Drug Toxicity — 2 reports (8.33%)
6. Hepatic Failure — 2 reports (8.33%)
7. Liver Disorder — 2 reports (8.33%)
8. Pneumonia Bacterial — 2 reports (8.33%)
9. Refractory Anaemia — 2 reports (8.33%)
10. Thrombocytopenia — 2 reports (8.33%)

Source database →

Frequently asked questions

Is antibiotic prophylaxis approved in United States?

antibiotic prophylaxis does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for antibiotic prophylaxis in United States?

The Central and Eastern European Gynecologic Oncology Group is the originator. The local marketing authorisation holder may differ — check the official source linked above.